Skip to main content


Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Fig. 4

Forest plot of risk ratios comparing treatment-related adverse events in patients who received IO-Chemotherapy vs Chemotherapy alone. The horizontal line crossing the dot represents the 95%CI of the pooled risk ratio in each subgroup-analysis. No. of trials refers to the number of trials included in each subgroup-analysis. I2 (P) shows the heterogeneity in each subgroup meta-analysis. aData provided in KEYNOTE-189 and KEYNOTE-407 were all-cause adverse events, regardless of attribution to any treatment. CI, confidence interval; RR, risk ratio; AEs, adverse events; IO, Immuno-oncology

Back to article page